Cello Health (LON:CLL) Stock Rating Reaffirmed by FinnCap

FinnCap restated their corporate rating on shares of Cello Health (LON:CLL) in a research note published on Thursday morning, ThisIsMoney.Co.Uk reports.

CLL opened at GBX 125.50 ($1.64) on Thursday. The business has a 50-day moving average price of GBX 125.38. Cello Health has a 12-month low of GBX 95 ($1.24) and a 12-month high of GBX 140.07 ($1.83). The company has a debt-to-equity ratio of 4.70, a current ratio of 1.28 and a quick ratio of 1.23. The stock has a market cap of $131.92 million and a PE ratio of 20.57.

In related news, insider Mark Bentley sold 129,800 shares of the stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of GBX 127 ($1.66), for a total transaction of £164,846 ($215,400.50).

Cello Health Company Profile

Cello Health plc, together with its subsidiaries, provides marketing services in the United Kingdom, Rest of Europe, the United States, and internationally. It operates in two segments, Cello Health and Cello Signal. The Cello Health segment offers market research, consulting, and communications services principally to the pharmaceutical and healthcare clients.

Recommended Story: Why do company’s buyback their stock?

Receive News & Ratings for Cello Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cello Health and related companies with MarketBeat.com's FREE daily email newsletter.